Trial Profile
A Phase 1 Single Dose PK Study in Adolescent Subjects With Fragile X Syndrome or Angelman Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Dec 2017
Price :
$35
*
At a glance
- Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
- Indications Angelman syndrome; Fragile X syndrome
- Focus Pharmacokinetics
- Sponsors Ovid Therapeutics
- 29 Nov 2017 Status changed from active, no longer recruiting to completed.
- 28 Nov 2017 Results published in the Media Release
- 28 Nov 2017 According to an Ovid Therapeutics media release, after successful completion of this trial, the company is planning to amend a Phase 2 trial (see profile 255964)and include adolescent patients aged 13 years and older in this trial.